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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Hungarian language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 206 JIA patients (3.9% systemic, 41.3% oligoarticular, 28.2% RF-negative polyarthritis, 
26.6% other categories) and 90 healthy children, were enrolled in two centres. The JAMAR components discriminated 
healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the 
Hungarian version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine 
clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Hungarian parent, child/adult version of 
the Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient-
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Hungarian language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from December 2011 
to April 2013. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, and 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of 
the illness (Yes/No) [15].The JAMAR is available in 
three versions, one for parent proxy-report (child’s age 
2–18), one for child self-report, with the suggested age 
range of 7–18 years, and one for adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to the international guidelines with 2–3 forward 
and backward translations. In those countries for which 
the translation of JAMAR had been already cross-cultural 
adapted in a similar language (i.e. Spanish in South Ameri-
can countries), only the probe technique was performed. 
Reading comprehension and understanding of the translated 
questionnaires were tested in a probe sample of 10 JIA par-
ents and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal item–scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproduc-
ibility of the JAMAR repeated after 1 or 2 weeks); and 
construct validity in its two components: the convergent 
or external validity which examines the correlation of the 
JAMAR sub-scales with the six JIA core set variables, with 
the addition of the parent assessment of disease activity 
and pain by the Spearman’s correlation coefficients (r) [17] 
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and the discriminant validity, which assesses whether the 
JAMAR discriminates between the different JIA categories 
and healthy children [18].Quantitative data were reported as 
medians with 1st and 3rd quartiles and categorical data as 
absolute frequencies and percentages.
The complete Hungarian parent and patient versions of 
the JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Hungarian JAMAR was fully cross-culturally adapted 
from the standard English version with three forward 
and three backward translations with a concordance for 
115/123 translation lines (93.5%) for the parent version 
and 111/120 lines (92.5%) for the child version.
In the probe technique analysis, the 123 lines were 
understood by 10/10 of the parents (median = 100%; range: 
100–100%). For the 120 lines of the patient version of 
the JAMAR all the lines were understood by at least 80% 
of the children (median = 100%; range: 100–100%). The 
texts of the parent JAMAR and of the child JAMAR were 
unmodified after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 206 JIA patients and 91 healthy children (total 
of 297 subjects) were enrolled at two paediatric rheumatol-
ogy centres. One healthy patient did not give the consent 
to use his/her data.
In the 206 JIA subjects, the JIA categories were 3.9% 
with systemic arthritis, 41.3% with oligoarthritis, 28.2% 
with RF-negative polyarthritis, 1.9% with RF positive 
polyarthritis, 4.8% with psoriatic arthritis, 16.0% with 
enthesitis-related arthritis and 3.9% with undifferentiated 
arthritis (Table 1).
All the subjects enrolled had the parent version of the 
JAMAR completed by a parent (206 from parents of JIA 
patients and 90 from parents of healthy children). The 
JAMAR was completed by 251/296 (84.8%) mothers and 
45/296 (15.2%) fathers. The child version of the JAMAR 
was completed by 254/296 (85.8%) children age 5.1 years 
or older. Also patients younger than 7 years old, capable to 
assess their personal condition and able to read and write, 
were asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the 
PF, the PhH, the PsH subscales and total score of the 
HRQoL scales. The JAMAR components discriminated 
well between healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. “Results” 
refers mainly to the parent’s version findings, unless other-
wise specified.
Descriptive statistics (first Likert assumption)
For all the JAMAR items the median number of missing 
responses was 0.5 (0.0–0.5).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items except for item 8, whereas a reduced number 
of response choices were used for all the PF items except 
for items 1, 3, 4, 11 and 13. The mean and SD of the items 
within a scale were roughly equivalent for the PF and for 
the HRQoL items (data not shown). The median number of 
items marked as not applicable was 2% (1–3%) for the PF 
and 5% (3–10%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 85.4% (79.1–90.3%) for the 
PF items, 56.3% (43.7–58.7%) for the HRQoL PhH items, 
and 58.3% (56.3–60.2%) for the HRQoL PsH items. The 
median ceiling effect was 0% (0-0.5%) for the PF items, 
3.4% (2.9–4.4%) for the HRQoL PhH items, and 1.5% 
(1-1.5%) for the HRQoL PsH items. The median floor effect 
was 39.3% for the pain VAS, 34.5% for the disease activity 
VAS and 36.9% for the well-being VAS. The median ceil-
ing effect was 0.0% for the pain VAS, 1.9% for the disease 
activity VAS and 0.0% for the well-being VAS.
Equal item–scale correlations (second Likert 
assumption)
Pearson item–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 93% of the PF 
items, with the exception of PF item 5, and for 90% of the 
HRQoL items with the exception of HRQoL item 1.
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Table 1  Descriptive statistics (medians, 1st–3rd quartiles or absolute frequencies and %) for the 206 JIA patients
Data related to the JAMAR refer to the 206 JIA patients and to the 90 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic Oligoarthritis RF−  poly-
arthritis
RF + poly-
arthritis
Psoriatic 
arthritis
Enthesitis-
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 8 N = 85 N = 58 N = 4 N = 10 N = 33 N = 8 N = 206 N = 90
Female 6 (75%) 66 (77.6%) 43 (74.1%) 2 (50%) 6 (60%) 5 (15.2%) 6 (75%) 134 (65%)# 48 (53.3%)
Age at visit 10.4 (6.2–14) 6.3 (4.4–9.8) 11.4 
(8.4–13.7)
14.1 
(10.1–17)
16.1 (10.5–
16.5)
14.3 
(12.7–16)
11 (6.4–14.7) 10.2 
(6.1–14.2)#
7.7 (5.8–
12.8)
Age at onset 4.6 (2.2–5.7) 3.1 (2-5.3) 5.9 (2.3–8.3) 9.4 (8.1–9.5) 11.3 
(5.7–13.1)
11.2 
(9.2–13.3)
7.9 (4.5–9.2) 5.4 (2.4–9.4)#
Disease duration 4.1 (2.5–9.1) 2.4 (1.2–4.3) 4.8 (2.9–7.5) 4.6 (2-7.5) 3.2 (2.4–4.8) 2.3 (1.4–4.4) 2.7 (1.2–5.6) 3 (1.5–5.6)**
ESR 5.5 (5–7) 9 (6–12) 10 (7–17.5) 7 (4–30) 18 (5–31) 6 (5–12) 10 (5–12) 9 (6–15)
MD VAS 
(0–10 cm)
2 (1–4) 2 (1–3) 2 (1–3) 3 (0–4) 2 (1.5-4) 1 (1–2) 2 (0–3) 2 (1–3)
No. of swollen 
joints
1 (0–5.5) 1 (0–2) 0 (0–2) 0 (0–1.5) 1.5 (0–2) 0 (0–2) 0.5 (0-1.5) 1 (0–2)
No. of joints with 
pain
0 (0–1) 0 (0–1) 0 (0–2) 1 (0–3) 1 (0–4) 0 (0–2) 0 (0–1) 0 (0–2)
No. of joints with 
LOM
8 (3–16.5) 2 (1–4) 6 (3–13) 2.5 (2–3.5) 4 (3–6) 2 (1–5) 1.5 (0.5–4.5) 3 (1–6)#
No. of active 
joints
1 (0–5.5) 1 (0–2) 1 (0–4) 1 (0–3) 2 (0–4) 1 (0–2) 0.5 (0–2) 1 (0–2)
Active systemic 
features
1 (12.5%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1/204 (0.5%)
ANA status 0 (0%) 29 (34.1%) 18 (31%) 1 (25%) 1 (10%) 3 (9.1%) 2 (25%) 54 (26.2%)*
Uveitis 0 (0%) 21/82 (25.6%) 5/56 (8.9%) 0 (0%) 0 (0%) 2/31 (6.5%) 0 (0%) 28/197 
(14.2%)*
PF total score 5.5 (2–16) 0 (0–2) 1 (0–4) 2.5 (0.5-4) 4 (1–8) 1 (0–4) 3 (0-8.5) 1 (0–4)* 0 (0–0)#
Pain VAS 3.3 (1–5) 0.5 (0–3) 1.3 (0–3) 0 (0–0) 1.3 (0–3) 1.5 (0–4) 1.5 (0-4.8) 1 (0–3) 0 (0–0)#
Disease activity 
VAS
3.5 (0.3–5) 1 (0–3.5) 2 (0–3) 0 (0–1) 1 (0–4) 1 (0–4.5) 0 (0–4.5) 1 (0–3.5)
Well-being VAS 2.8 (0.5–5) 0.5 (0–3) 1.8 (0–3) 0.5 (0–2.3) 1.5 (0–3.5) 1 (0–4) 2 (0–5) 1 (0–3)
HRQoL PhH 3.5 (2–6) 2 (0–4) 2 (0–4) 1.5 (0.5-4) 5 (4–5) 2 (1–4) 2 (0.5–4.5) 2 (1–4) 0 (0–0)#
HRQoL PsH 4 (3–6) 2 (0–4) 1 (0–3) 1.5 (0-4.5) 3.5 (2–4) 2 (0–5) 2 (0.5–4.5) 2 (0–4) 0 (0–0)#
HRQoL total 
score
8 (5.5–12) 5 (1–9) 3 (2–7) 4.5 (0.5–8.5) 8 (7–13) 4 (2–8) 5.5 (1–8.5) 4 (1–9) 0 (0–0)#
Pain/swell. in > 1 
joint
6 (75%) 45 (52.9%) 39 (67.2%) 2 (50%) 6 (60%) 17 (51.5%) 4 (50%) 119 (57.8%) 2 (2.2%)#
Morning stiff-
ness > 15 min
3 (37.5%) 11 (12.9%) 7 (12.1%) 0 (0%) 2 (20%) 7 (21.2%) 1 (12.5%) 31 (15%) 0 (0%)**
Subjective remis-
sion
5 (62.5%) 35 (41.2%) 34/57 (59.6%) 1 (25%) 4 (40%) 14 (42.4%) 4 (50%) 97/205 
(47.3%)
In treatment 7 (87.5%) 69 (81.2%) 51 (87.9%) 4 (100%) 7 (70%) 31 (93.9%) 7 (87.5%) 176 (85.4%)
Reporting side 
effects
1/7 (14.3%) 18/69 (26.1%) 15/51 (29.4%) 2 (50%) 1/7 (14.3%) 4/31 (12.9%) 2/7 (28.6%) 43/176 
(24.4%)
Taking medication 
regularly
7/7 (100%) 67/69 (97.1%) 49/51 (96.1%) 4 (100%) 7/7 (100%) 29/31 (93.5%) 7/7 (100%) 170/176 
(96.6%)
With problems 
attending school
1/4 (25%) 4/26 (15.4%) 6/34 (17.6%) 1/3 (33.3%) 3/6 (50%) 4/19 (21.1%) 0 (0%) 19/96 (19.8%) 0 (0%)#
Satisfied with dis-
ease outcome
6 (75%) 71 (83.5%) 48/56 (85.7%) 4 (100%) 9 (90%) 26 (78.8%) 5 (62.5%) 169/204 
(82.8%)
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Items internal consistency (third Likert assumption)
Pearson item–scale correlations were ≥ 0.4 for 100% of 
items of the PF and 100% of items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.88 for PF-LL, 0.81 for PF-HW, 0.85 
for PF-US. Cronbach’s alpha was 0.86 for HRQoL-PhH and 
0.83 for HRQoL-PsH.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial Health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 206/296 Child N = 188/254
Missing values (1st–3rd quartiles) 0.5 (0.0–0.5) 0.0 (0.0–0.5)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 85.4% 85.6%
 HRQoL PhH 56.3% 64.4%
 HRQoL PsH 58.3% 66.0%
 Pain VAS 39.3% 39.4%
 Disease activity VAS 34.5% 38.8%
 Well-being VAS 36.9% 41.0%
Ceiling effect, median
 PF 0.0% 1.1%
 HRQoL PhH 3.4% 4.3%
 HRQoL PsH 1.5% 1.1%
 Pain VAS 0.0% 0.5%
 Disease activity VAS 1.9% 1.6%
 Well-being VAS 0.0% 0.0%
Items with equivalent item–scale correlation 93% for PF, 90% for HRQoL 93% for PF, 90% for HRQoL
Items with item–scale correlation ≥ 0.4 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.88 0.81
 PF-HW 0.81 0.85
 PF-US 0.85 0.83
 HRQoL-PhH 0.86 0.83
 HRQoL-PsH 0.83 0.79
Items with item–scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 1.0 0.80
 HRQoL-PhH 0.98 1.0
 HRQoL-PsH 0.93 0.93
Spearman correlation with JIA core set variables, median
 PF 0.5 0.5
 HRQoL PhH 0.5 0.4
 HRQoL PsH 0.4 0.3
 Pain VAS 0.4 0.3
 Disease activity VAS 0.4 0.4
Well-being VAS 0.4 0.4
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Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 20 JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after a 
median of 0 days (0–7 days). The intraclass correlation coef-
ficients (ICC) for the PF total score showed an almost perfect 
reproducibility (ICC = 1.0). The ICC for the HRQoL PhH 
and for the HRQoL PsH showed an almost perfect reproduc-
ibility (ICC = 0.98 and ICC = 0.93, respectively).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.4 to 0.6 
(median = 0.5). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.6, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged from 
0.3 to 0.7 (median = 0.5), whereas for the PsH ranged from 
0.2 to 0.5 (median = 0.4). The PhH showed the best correla-
tion with the parent’s assessment of pain (r = 0.7, p < 0.001) 
and the PsH with the parent global assessment of well-being 
(r = 0.6, p < 0.001). The median correlations between the 
pain VAS, the well-being VAS, and the disease activity VAS 
and the physician-centred and laboratory measures were 0.4 
(0.2–0.5), 0.4 (0.3–0.5), 0.4 (0.3–0.5), respectively.
Discussion
In this study, the Hungarian version of the JAMAR was 
cross-culturally adapted from the original standard English 
version with three forward and three backward translations. 
According to the results of the validation analysis, the Hun-
garian parent and patient versions of the JAMAR possess 
satisfactory psychometric properties. The disease-specific 
components of the questionnaire discriminated well between 
patients with JIA and healthy controls. The PF total score 
proved to discriminate between the different JIA subtypes 
with children with systemic arthritis having a higher degree 
of disability.
Psychometric performances were good for all domains of 
the JAMAR and the overall internal consistency was good 
for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters were moderate.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents.
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Hungarian version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
Acknowledgements We thank all families who participated in the pro-
ject, the team that prepared and reviewed the forward and backward 
translations, and all members of PRINTO in Hungary. We thank the 
staff of the PRINTO International Coordinating Centre in Genoa (Italy) 
and in particular Marco Garrone for the overall coordination of the 
translation process, Silvia Scala and Elisa Patrone for data collection 
and quality assurance; Luca Villa, Giuseppe Silvestri and Mariangela 
Rinaldi for the database development and management and the remain-
ing PRINTO team for data entry. The principal investigator of the study 
was Prof. Angelo Ravelli, MD. The scientific coordinator and study 
methodologist was Nicolino Ruperto, MD, MPH. The project coordi-
nators were Alessandro Consolaro, MD, PhD, Francesca Bovis, BsA. 
We thank also Prof. Alberto Martini, PRINTO Chairman. Funding was 
provided by the Istituto G. Gaslini, Genoa (Italy). Permission for use of 
JAMAR and its translations must be obtained in writing from PRINTO, 
Genoa, Italy. All JAMAR-related inquiries should be directed to at 
printo@gaslini.org. Permission for use of CHAQ and CHQ-derived 
material is granted through the scientific cooperation of the copyright 
holder ICORE of Woodside CA and HealthActCHQ Inc. of Boston, 
Massachusetts USA. All CHQ-related inquiries should be directed to 
licensing@healthactchq.com. All CHAQ-related inquiries should be 
directed to gsingh@stanford.edu.
Funding This study was funded and coordinated by Istituto Giannina 
Gaslini, Genoa, Italy.
Compliance with ethical standards 
Conflict of interest Dr. Ponyi, Dr. Kiss, Dr. Orbán, Dr. Constantin, Dr. 
Derfalvi, Dr. Sevcic and Dr. Poór report funding support from Istituto 
Giannina Gaslini, Genoa, Italy, for the translation and data collection 
performed at their sites within the EPOCA project. Dr. Ruperto has re-
ceived grants from BMS, Hoffman-La Roche, Janssen, Novartis, Pfiz-
er, Sobi, during the conduct of the study and personal fees and speaker 
honorarium from Abbvie, Ablynx, Amgen, AstraZeneca, Baxalta Bio-
similars, Biogen Idec, Boehringer, Bristol Myers Squibb, Celgene, Eli-
Lilly, EMD Serono, Gilead Sciences, Janssen, Medimmune, Novartis, 
Pfizer, Rpharm, Roche, Sanofi, Servier and Takeda. Dr. Consolaro, Dr. 
Bovis, Dr. Garan and Dr. Kaposzta have nothing to disclose.
Ethical approval All procedures performed in studies involving human 
participants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964 Helsinki 
Declaration and its later amendments or comparable ethical standards.
S249Rheumatology International (2018) 38 (Suppl 1):S243–S250 
1 3
Informed consent Informed consent was obtained from all individual 
participants included in the study as per the requirement of the local 
ethical committee.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Filocamo G, Consolaro A, Schiappapietra B, Dalpra S, Lattanzi 
B, Magni-Manzoni S et al (2011) A new approach to clinical care 
of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimen-
sional Assessment Report. J Rheumatol 38(5):938–953
 2. Ruperto N, Martini A (2011) Networking in paediatrics: the exam-
ple of the paediatric rheumatology international trials organisation 
(PRINTO). Arch Dis Child 96(6):596–601
 3. Consolaro A, Ruperto N, Filocamo G, Lanni S, Bracciolini G, 
Garrone M et al (2012) Seeking insights into the epidemiology, 
treatment and outcome of childhood arthritis through a multi-
national collaborative effort: introduction of the EPOCA study. 
Pediatr Rheumatol Online J 10(1):39
 4. Bovis F, Consolaro A, Pistorio A, Garrone M, Scala S, Patrone 
E et al (2018) Cross-cultural adaptation and psychometric evalu-
ation of the Juvenile Arthritis Multidimensional Assessment 
Report (JAMAR) in 54 languages across 52 countries: review of 
the general methodology. Rheumatol Int. https ://doi.org/10.1007/
s0029 6-018-3944-1 (in this issue)
 5. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Man-
ners P et al (1998) Revision of the proposed classification crite-
ria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 
25(10):1991–1994
 6. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Golden-
berg J et al (2004) International league of associations for rheuma-
tology classification of juvenile idiopathic arthritis: second revi-
sion, Edmonton, 2001. J Rheumatol 31(2):390–392
 7. Filocamo G, Sztajnbok F, Cespedes-Cruz A, Magni-Manzoni S, 
Pistorio A, Viola S et al (2007) Development and validation of a 
new short and simple measure of physical function for juvenile 
idiopathic arthritis. Arthritis Rheum 57(6):913–920
 8. Lovell DJ, Howe S, Shear E, Hartner S, McGirr G, Schulte M et al 
(1989) Development of a disability measurement tool for juvenile 
rheumatoid arthritis. The juvenile arthritis functional assessment 
scale. Arthritis Rheum 32:1390–1395
 9. Howe S, Levinson J, Shear E, Hartner S, McGirr G, Schulte M 
et al (1991) Development of a disability measurement tool for 
juvenile rheumatoid arthritis. The juvenile arthritis functional 
assessment report for children and their parents. Arthritis Rheum 
34:873–880
 10. Singh G, Athreya BH, Fries JF, Goldsmith DP (1994) Measure-
ment of health status in children with juvenile rheumatoid arthri-
tis. Arthritis Rheum 37:1761–1769
 11. Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lat-
tanzi B et al (2010) Evaluation of 21-numbered circle and 10-cen-
timeter horizontal line visual analog scales for physician and par-
ent subjective ratings in juvenile idiopathic arthritis. J Rheumatol 
37(7):1534–1541
 12. Duffy CM, Arsenault L, Duffy KN, Paquin JD, Strawczynski H 
(1997) The juvenile arthritis quality of life questionnaire—devel-
opment of a new responsive index for juvenile rheumatoid arthritis 
and juvenile spondyloarthritides. J Rheumatol 24(4):738–746
 13. Varni JW, Seid M, Knight TS, Burwinkle T, Brown J, Szer IS 
(2002) The PedsQL(TM) in pediatric rheumatology—reliability, 
validity, and responsiveness of the pediatric quality of life inven-
tory (TM) generic core scales and rheumatology module. Arthritis 
Rheum 46(3):714–725
 14. Landgraf JM, Abetz L, Ware JE (1996) The CHQ user’s manual. 
First Edition. The Health Institute, New England Medical Center, 
Boston
 15. Filocamo G, Consolaro A, Schiappapietra B, Ruperto N, Pistorio 
A, Solari N et al (2012) Parent and child acceptable symptom state 
in juvenile idiopathic arthritis. J Rheumatol 39(4):856–863
 16. Nunnally JC (1978) Psychometric theory, 2nd edn. McGraw-Hill, 
New York
 17. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Mar-
tini A (1997) Preliminary definition of improvement in juvenile 
arthritis. Arthritis Rheum 40(7):1202–1209
 18. Ware JE Jr, Harris WJ, Gandek B, Rogers BW, Reese PR (1997) 
MAP-R for windows: multitrait/multi-item analysis program—
revised user’s guide. Version 1.0 ed. Health Assessment Lab, 
Boston
Affiliations
Ilonka Orbán1 · Tamás Constantin2 · Beáta Dérfalvi2 · Krisztina Sevcic1 · Diána Garan2 · Rita Káposzta3 · Gyula Poór1 · 
Emese Kiss1 · Andrea Ponyi2 · Alessandro Consolaro4,5 · Francesca Bovis4 · Nicolino Ruperto4 · For the Paediatric 
Rheumatology International Trials Organisation (PRINTO)
 Tamás Constantin 
 tamasconstantin@gmail.com
 Beáta Dérfalvi 
 derfalv@gyer1.sote.hu
 Krisztina Sevcic 
 sevcic.krisztina@orfi.hu
 Diána Garan 
 dianagaran@gmail.com
 Rita Káposzta 
 kaposta@dote.hu
 Gyula Poór 
 pgyula@orfi.hu
 Emese Kiss 
 kissemese@freemail.hu
 Andrea Ponyi 
 ponyiandrea@hotmail.com
S250 Rheumatology International (2018) 38 (Suppl 1):S243–S250
1 3
 Alessandro Consolaro 
 alessandroconsolaro@gaslini.org
 Francesca Bovis 
 francescabovis@gaslini.org
1 Clinical Immunology, Adult- and Paediatric Rheumatology 
Department, National Institute of Rheumatology 
and Physiotherapy, Frankel Leo Str. 38-40, 1023 Budapest, 
Hungary
2 Unit of Pediatric Rheumatology-Immunology, 2nd 
Department of Pediatrics, Semmelweis University, Budapest, 
Hungary
3 Department of Pediatrics, University of Debrecen, Debrecen, 
Hungary
4 Clinica Pediatrica e Reumatologia, Paediatric Rheumatology 
International Trials Organisation (PRINTO), Istituto 
Giannina Gaslini, Via Gaslini 5, 16147 Genoa, Italy
5 Dipartimento di Pediatria, Università di Genova, Genoa, Italy
